Erik Harris, EVP and Chief Commercial Officer at Ultragenyx Pharmaceutical Inc. ($RARE), made one open market sale of company shares in the last year, totaling about $240 thousand. His most recent sale occurred on March 2, 2026. This places him 8,047th out of 11,678 insiders by sale value in our database, well below the average of $8.6 million across 6.4 transactions per insider. He recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 10539 | $22.80 | 89,515.0000 | 98,600,000 | 10.53% | 0.01% |
| March 1, 2026 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 11643 | $0.00 | 99,498.0000 | 98,600,000 | 13.25% | 0.01% |
| Nov. 19, 2025 | Rezolute, Inc. | $RZLT | Harris Erik | Not found | A | Common Shares | 21000 | $0.00 | 21,000.0000 | 103,422,647 | 9999.99% | 0.02% |
| Nov. 19, 2025 | Rezolute, Inc. | $RZLT | Harris Erik | Not found | A | Director Stock Option (Right to Buy) | 12000 | $0.00 | 12,000.0000 | 103,422,647 | 9999.99% | 0.01% |
| March 25, 2025 | Rezolute, Inc. | $RZLT | Harris Erik | Not found | A | Director Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 69,940,319 | 9999.99% | 0.09% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Stock Option (Right to Buy) | 30246 | $0.00 | 30,246.0000 | 90,538,118 | 9999.99% | 0.03% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 18443 | $0.00 | 102,419.0000 | 90,538,118 | 21.96% | 0.02% |
| March 3, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 15103 | $42.10 | 87,855.0000 | 90,538,118 | 14.67% | 0.02% |
| March 1, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 16813 | $0.00 | 83,976.0000 | 90,538,118 | 25.03% | 0.02% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Harris Erik | Director | A | Common Stock | 5967 | $0.00 | 17,052.0000 | 137,370,897 | 53.83% | 0.00% |
| May 31, 2024 | Denali Therapeutics Inc. | $DNLI | Harris Erik | Director | A | Stock Option (right to buy) | 17901 | $0.00 | 17,901.0000 | 137,370,897 | 9999.99% | 0.01% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 957 | $0.00 | 71,638.0000 | 73,543,862 | 1.35% | 0.00% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 4768 | $53.76 | 67,163.0000 | 73,543,862 | 6.63% | 0.01% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Stock Option (Right to Buy) | 34200 | $0.00 | 34,200.0000 | 73,543,862 | 9999.99% | 0.05% |
| March 1, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 19400 | $0.00 | 70,681.0000 | 73,543,862 | 37.83% | 0.03% |
| Sept. 5, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 6000 | $37.96 | 51,281.0000 | 69,914,225 | 10.47% | 0.01% |
| June 19, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 305 | $48.20 | 57,281.0000 | 69,914,225 | 0.53% | 0.00% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 2663 | $0.00 | 38,823.0000 | 69,914,225 | 7.36% | 0.00% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Common Stock | 22000 | $0.00 | 60,823.0000 | 69,914,225 | 56.67% | 0.03% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | S | Common Stock | 3664 | $45.25 | 57,344.0000 | 69,914,225 | 6.01% | 0.01% |
| March 1, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Harris Erik | EVP & Chief Commercial Officer | A | Stock Option (Right to Buy) | 39400 | $0.00 | 39,400.0000 | 69,914,225 | 9999.99% | 0.06% |